The study is intended to estimate the proportion and clinical management of people with type 2 diabetes having atherosclerotic cardiovascular diseases or who are at high risk to develop atherosclerotic cardiovascular diseases. Participants will be asked to give information about their health. Partipants will continue normal way of life and will not get any medication other than those prescribed to them by the doctor. The study will last for about 6 months.
Study Type
OBSERVATIONAL
Enrollment
4,089
The clinical management and prescribed treatment of diabetes and eASCVD/ASCVD risk factors are independent of this study and are part of the routine clinical practice at the discretion of the treating physician.
Novo Nordisk Investigational Site
Manama, Bahrain
Novo Nordisk Investigational Site
Alexandria, Egypt
Novo Nordisk Investigational Site
Amman, Jordan
Novo Nordisk Investigational Site
As Sālimīyah, Kuwait
Novo Nordisk Investigational Site
Doha, Qatar
Novo Nordisk Investigational Site
Johannesburg, South Africa
Novo Nordisk Investigational Site
Abu Dhabi, United Arab Emirates
Proportion of patients with Established Atherosclerotic Cardiovascular Disease (eASCVD) pooled across all countries and separately for each country in scope
Percentage patients
Time frame: At the time of patient enrolment (Day 1)
Proportion of T2D patients with high risk of Atherosclerotic cardiovascular disease (ASCVD) and without eASCVD
Percentage patients
Time frame: At the time of patient enrolment (Day 1)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.